[{"id":"3a78f5b1-8ba2-481a-a8fe-73c711e0e9a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03375242","created_at":"2021-01-18T16:39:27.774Z","updated_at":"2025-02-25T14:39:49.048Z","phase":"","brief_title":"Safety and Efficacy of Xalkori ROS1","source_id_and_acronym":"NCT03375242","lead_sponsor":"Pfizer","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/25/2017","start_date":" 10/25/2017","primary_txt":" Primary completion: 08/24/2026","primary_completion_date":" 08/24/2026","study_txt":" Completion: 08/24/2026","study_completion_date":" 08/24/2026","last_update_posted":"2025-02-14"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"aecf3ac5-9504-4f3a-9a5f-7cc5aaedb65d","acronym":"NCI-2019-03212","url":"https://clinicaltrials.gov/study/NCT03965689","created_at":"2021-01-18T19:30:37.082Z","updated_at":"2024-07-02T16:35:02.796Z","phase":"Phase 2","brief_title":"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy","source_id_and_acronym":"NCT03965689 - NCI-2019-03212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression","tags":["BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2024-05-17"},{"id":"8e698f4d-2a78-42c5-a620-76e572d7431e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595059","created_at":"2021-01-18T17:40:37.713Z","updated_at":"2024-07-02T16:35:05.958Z","phase":"Phase 1","brief_title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","source_id_and_acronym":"NCT03595059","lead_sponsor":"AbbVie","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"},{"id":"8d11e7de-5fd7-49f6-b0e9-31e7346e7fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04800822","created_at":"2021-03-16T14:52:26.431Z","updated_at":"2024-07-02T16:35:06.982Z","phase":"Phase 1","brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04800822","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1 • NF1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive","tags":["ALK • ROS1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/18/2024","primary_completion_date":" 06/18/2024","study_txt":" Completion: 11/29/2025","study_completion_date":" 11/29/2025","last_update_posted":"2024-04-30"},{"id":"eaa7905b-c46a-428c-a893-85ea9fe3af9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441956","created_at":"2022-07-01T20:56:47.697Z","updated_at":"2024-07-02T16:35:10.474Z","phase":"Phase 1","brief_title":"TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05441956","lead_sponsor":"Shenzhen TargetRx, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e deulorlatinib (TGRX-326)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-04-10"},{"id":"e41c6423-6ebc-477e-83c1-0ab041388c50","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT05770544","created_at":"2023-03-15T14:02:36.092Z","updated_at":"2024-07-02T16:35:20.432Z","phase":"Phase 2/3","brief_title":"DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.","source_id_and_acronym":"NCT05770544 - DETERMINE","lead_sponsor":"Cancer Research UK","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion • ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-02-07"},{"id":"6804ad4f-366a-409e-96a1-52960e5c0655","acronym":"","url":"https://clinicaltrials.gov/study/NCT03646994","created_at":"2021-01-18T17:54:06.877Z","updated_at":"2024-07-02T16:35:25.188Z","phase":"","brief_title":"Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03646994","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-27"},{"id":"e8106815-807d-440d-af1d-1076b6e5a743","acronym":"","url":"https://clinicaltrials.gov/study/NCT05318443","created_at":"2022-04-08T21:52:56.841Z","updated_at":"2024-07-02T16:35:25.142Z","phase":"Phase 3","brief_title":"A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05318443","lead_sponsor":"Shanghai Institute Of Biological Products","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • SIBP-04 (bevacizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 512","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 12/26/2022","primary_completion_date":" 12/26/2022","study_txt":" Completion: 01/12/2023","study_completion_date":" 01/12/2023","last_update_posted":"2023-12-27"},{"id":"03b258b9-b6b1-4be5-9722-9374ceff289d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03917043","created_at":"2021-09-06T03:53:55.845Z","updated_at":"2024-07-02T16:35:28.475Z","phase":"Phase 1","brief_title":"APG-2449 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03917043","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-2449"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-11-21"},{"id":"5f9804b9-88fc-46a5-bcd4-30a909e6dda8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01970865","created_at":"2021-01-17T17:11:22.323Z","updated_at":"2024-07-02T16:35:46.223Z","phase":"Phase 1/2","brief_title":"A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations","source_id_and_acronym":"NCT01970865","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ALK mutation • ROS1 positive • ROS1 rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ALK mutation • ROS1 positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 01/08/2014","start_date":" 01/08/2014","primary_txt":" Primary completion: 03/15/2017","primary_completion_date":" 03/15/2017","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2023-06-07"},{"id":"6ed7310f-1b32-4649-afa5-8be315afc925","acronym":"","url":"https://clinicaltrials.gov/study/NCT05765877","created_at":"2023-03-13T15:02:23.189Z","updated_at":"2024-07-02T16:35:53.504Z","phase":"Phase 2","brief_title":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05765877","lead_sponsor":"Pingping Song","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-03-13"},{"id":"366454f1-0117-4368-836e-a2c60b023fbd","acronym":"I-SABR","url":"https://clinicaltrials.gov/study/NCT03825510","created_at":"2021-01-18T18:53:37.261Z","updated_at":"2024-07-02T16:35:54.017Z","phase":"Phase 2","brief_title":"Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect","source_id_and_acronym":"NCT03825510 - I-SABR","lead_sponsor":"Crozer-Keystone Health System","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ROS1 positive","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 04/28/2017","start_date":" 04/28/2017","primary_txt":" Primary completion: 03/08/2022","primary_completion_date":" 03/08/2022","study_txt":" Completion: 03/08/2022","study_completion_date":" 03/08/2022","last_update_posted":"2023-03-06"},{"id":"5d646b6c-e72c-4c25-be57-6c6c7bb08c0a","acronym":"REGOMUNE","url":"https://clinicaltrials.gov/study/NCT03475953","created_at":"2021-01-18T17:07:36.724Z","updated_at":"2025-02-25T16:07:43.432Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","source_id_and_acronym":"NCT03475953 - REGOMUNE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1 • BRAF • ALK • TMB • MSI • ROS1 • CTLA4","pipe":" | ","alterations":" TMB-H • ALK positive • ALK mutation • ROS1 positive","tags":["PD-L1 • BRAF • ALK • TMB • MSI • ROS1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • ALK positive • ALK mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 747","initiation":"Initiation: 05/04/2018","start_date":" 05/04/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-03"},{"id":"e9474c39-1ad6-4925-9b2b-111e2d5459c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420742","created_at":"2021-01-18T16:52:33.735Z","updated_at":"2024-07-02T16:35:56.843Z","phase":"Phase 1","brief_title":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","source_id_and_acronym":"NCT03420742","lead_sponsor":"Takeda","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 03/24/2020","primary_completion_date":" 03/24/2020","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-01-27"},{"id":"f940d82e-06f2-44db-8afc-37bc80ceac97","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996121","created_at":"2021-08-09T13:53:04.483Z","updated_at":"2025-02-25T17:11:55.305Z","phase":"Phase 1/2","brief_title":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04996121","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" ROS1 • NTRK","pipe":" | ","alterations":" ROS1 fusion • ROS1 positive • NTRK fusion","tags":["ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ROS1 positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XZP-5955"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2022-08-30"},{"id":"dd978514-327b-471f-bca4-d5ae648797aa","acronym":"EUCROSS","url":"https://clinicaltrials.gov/study/NCT02183870","created_at":"2021-01-18T10:11:21.603Z","updated_at":"2024-07-02T16:36:08.630Z","phase":"Phase 2","brief_title":"EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer","source_id_and_acronym":"NCT02183870 - EUCROSS","lead_sponsor":"University of Cologne","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion • ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 07/24/2018","primary_completion_date":" 07/24/2018","study_txt":" Completion: 02/29/2020","study_completion_date":" 02/29/2020","last_update_posted":"2022-06-16"},{"id":"c7d416a9-6875-4805-a5c3-b535a1527d5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02679170","created_at":"2021-01-18T13:03:52.943Z","updated_at":"2024-07-02T16:36:09.085Z","phase":"","brief_title":"Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK\u0026ROS)","source_id_and_acronym":"NCT02679170","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ROS1 positive • ALK translocation","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ROS1 positive • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 06/29/2016","start_date":" 06/29/2016","primary_txt":" Primary completion: 05/04/2022","primary_completion_date":" 05/04/2022","study_txt":" Completion: 05/04/2022","study_completion_date":" 05/04/2022","last_update_posted":"2022-06-10"},{"id":"ec6888d8-8567-44a4-9538-6cdb2ce914b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05055232","created_at":"2021-09-24T14:55:06.174Z","updated_at":"2025-02-25T17:12:00.677Z","phase":"Phase 1","brief_title":"A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05055232","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xuan Fei Ning (dirozalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/12/2023","primary_completion_date":" 03/12/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2021-09-24"},{"id":"74935b5a-a7e9-4357-95ea-10d54e3b1962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04237805","created_at":"2021-01-17T17:53:59.682Z","updated_at":"2024-07-02T16:36:28.174Z","phase":"Phase 1/2","brief_title":"A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04237805","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e foritinib (SAF-189)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2021-07-08"},{"id":"7eddd5df-83e2-4fd2-9042-aff3d4c30398","acronym":"","url":"https://clinicaltrials.gov/study/NCT03568539","created_at":"2021-01-18T06:59:19.098Z","updated_at":"2024-07-02T16:36:29.642Z","phase":"Phase 1b","brief_title":"IBI308 in Subjects With Advanced/Metastatic Solid Malignancies","source_id_and_acronym":"NCT03568539","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" ALK • TMB • ROS1","pipe":" | ","alterations":" EGFR mutation • TMB-H • ALK rearrangement • ROS1 positive","tags":["ALK • TMB • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • TMB-H • ALK rearrangement • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 11/09/2020","primary_completion_date":" 11/09/2020","study_txt":" Completion: 12/07/2020","study_completion_date":" 12/07/2020","last_update_posted":"2021-06-01"},{"id":"ce28c372-7763-4606-bef0-0f465abf3744","acronym":"","url":"https://clinicaltrials.gov/study/NCT04292119","created_at":"2021-01-18T20:49:43.053Z","updated_at":"2024-07-02T16:36:33.523Z","phase":"Phase 1/2","brief_title":"Lorlatinib Combinations in Lung Cancer","source_id_and_acronym":"NCT04292119","lead_sponsor":"Massachusetts General Hospital","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • ROS1 positive • ROS1 rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • batoprotafib (TNO155)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-03-10"},{"id":"8ebf976b-238e-421b-8483-823d7b4e244d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641754","created_at":"2021-01-19T20:38:48.770Z","updated_at":"2024-07-02T16:36:38.236Z","phase":"Phase 2","brief_title":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04641754","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Qi Xinke (iruplinalkib)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 03/07/2019","start_date":" 03/07/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2020-11-24"}]